EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Three-year outcomes of surgical bleb revision with mitomycin C for early scarring bleb after trabeculectomy

Risa Caraher-Masuda, Mari Sakamoto, Mina Okuda, Fumio Takano, Sotaro Mori, Kaori Ueda, Akiyasu Kanamori, Yuko Yamada-Nakanishi, Makoto Nakamura

Japanese Journal of Ophthalmology · 2025

DOI: 10.1007/s10384-024-01142-7 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Risa Caraher-Masuda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. Hauptthemen laut MEDLINE: Mitomycin, Trabeculectomy, Glaucoma, Postoperative Complications. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kobe University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To report the 3-year outcomes of surgical bleb revision (SBR) with mitomycin C (MMC) for early scarring bleb after trabeculectomy (TLE). Study design Retrospective observational study.

Methods

We included glaucoma patients aged ≧ 18 who underwent SBR with MMC within 6 months of their first TLE at Kobe University Hospital and were followed for at least 6 months. The primary outcome measure was the three-year success rate of SBR. We defined surgical success as: intraocular pressure (IOP) reduction ≧ 20% from baseline and 5 ≦ IOP ≦ 18 mmHg. Failure was defined when the IOP deviated from the criteria, when the eye required additional glaucoma surgery, and when the eye lost light perception. Complete success (CS) was success without glaucoma medications and qualified success (QS) was success with glaucoma medications. The secondary outcome measures included IOP, the number of glaucoma medications, mean deviation (MD), best corrected visual acuity (BCVA), corneal endothelial cell density (ECD), and surgical complications.

Results

Sixty-eight eyes of 68 patients were analyzed. The median interval between initial TLE and SBR was 2 months. Overall success rate at three-year after SBR were 45.1% and 9.6% for QS and CS, respectively. A greater number of medications used before TLE was a contributing factor to failure ( P = 0.02). 22 eyes (32.4%) underwent additional glaucoma surgery, and 41 eyes (60.3%) were spared from additional glaucoma surgery within 3 years after SBR. The median IOP decreased form 24.0 mmHg to 11.0 mmHg 3 years after SBR, and the number of medications decreased from 4 to 2 ( P < 0.01). MD remained unchanged, but BCVA and ECD decreased at 3years postoperatively. There were no serious complications of SBR.

Conclusion

SBR may be an effective treatment option for early scarring blebs after TLE but is unsuccessful in eyes that have used many glaucoma medications prior to TLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitomycinTrabeculectomyGlaucomaPostoperative ComplicationsCicatrixHumansRetrospective StudiesMaleFemaleIntraocular PressureVisual AcuityFollow-Up StudiesMiddle AgedReoperationAgedAlkylating AgentsTreatment OutcomeTime FactorsAged, 80 and overAdult

Stichwörter der Autor:innen

Bleb revisionGlaucomaNeedlingTrabeculectomy

Substanzen

MitomycinAlkylating Agents

Autor:innen und Institutionen

  • Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
  • Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan. mariwsakamoto@people.kobe-u.ac.jp.
  • Kanamori Eye Clinic, Kobe, Japan.

Förderung

  • Kobe University

Zitieren

APA

Caraher-Masuda, R., Sakamoto, M., Okuda, M., Takano, F., Mori, S., Ueda, K., Kanamori, A., Yamada-Nakanishi, Y., & Nakamura, M. (2025). Three-year outcomes of surgical bleb revision with mitomycin C for early scarring bleb after trabeculectomy. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-024-01142-7

Vancouver

Caraher-Masuda R, Sakamoto M, Okuda M, Takano F, Mori S, Ueda K, et al. Three-year outcomes of surgical bleb revision with mitomycin C for early scarring bleb after trabeculectomy. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-024-01142-7

BibTeX
@article{CaraherMasuda2025,
  author = {Caraher-Masuda, Risa and Sakamoto, Mari and Okuda, Mina and Takano, Fumio and Mori, Sotaro and Ueda, Kaori and Kanamori, Akiyasu and Yamada-Nakanishi, Yuko and Nakamura, Makoto},
  title = {Three-year outcomes of surgical bleb revision with mitomycin C for early scarring bleb after trabeculectomy},
  journal = {Japanese Journal of Ophthalmology},
  year = {2025},
  doi = {10.1007/s10384-024-01142-7}
}
Kostenlos starten →